Codexis Newswire

Comprehensive Real-Time News Feed for Codexis.

Results 1 - 20 of 27 in Codexis

  1. Codexis, Inc. To Report Third Quarter 2014 Financial Results On November 4Read the original story

    Tuesday Oct 21 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report third quarter financial results after the close of market on November 4, followed at 4:30 p.m. Eastern Time by a conference call and audio webcast at www.codexis.com . Codexis, Inc. is a leading developer of biocatalysts for pharmaceutical and fine chemical production.

    Comment?

  2. Codexis, Inc. Appoints Biotechnology Industry Veteran, To Board Of DirectorsRead the original story

    Sep 22, 2014 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Kathleen Sereda Glaub to its board of directors. Ms. Glaub's 30-year career in leadership positions with drug development and technology companies will bring strong company-building and business strategy experience to the Codexis board.

    Comment?

  3. Rising Prominence of Sustainable Production Practices Drives the...Read the original story

    Sep 19, 2014 | PRWeb

    ... Ltd., Amano Enzyme Inc., Asahi Kasei Pharma Corporation, BASF SE, BioResource International Inc., Chr. Hansen A/S, Codexis Inc., DuPont Nutrition and Health, Direvo Biotech AG, Enzymatic Deinking Technologies LLC, Hayashibara Company, Novozymes A/S, ...

    Comment?

  4. Codexis Director Acquires $133,200 in StockRead the original story

    Aug 18, 2014 | AmericanBankingNews.com

    Codexis Director Patrick Y. Yang acquired 60,000 shares of Codexis stock in a transaction that occurred on Tuesday, August 12th.

    Comment?

  5. Codexis Director Patrick Y. Yang Buys 60,000 SharesRead the original story

    Aug 14, 2014 | AmericanBankingNews.com

    Codexis Director Patrick Y. Yang bought 60,000 shares of the stock in a transaction that occurred on Tuesday, August 12th.

    Comment?

  6. Egalet Announces Topline Results From Egalet-001; Geron to Assume...Read the original story

    Aug 6, 2014 | Hispanic Business

    Study 067-EG-005 evaluated the area under the curve and the maximum or peak plasma concentration of -001 100 mg versus the same dose of MS Contin in a fasted state in 58 subjects.

    Comment?

  7. Codexis' (CDXS) CEO John Nicols on Q2 2014 Results - Earnings Call TranscriptRead the original story

    Aug 6, 2014 | Seeking Alpha

    Welcome to Codexis second quarter earnings conference call. This call is being webcast live on the investor's section of Codexis' website at codexis.com.

    Comment?

  8. Codexis Reports Financial Results for the Second Quarter of 2014Read the original story

    Aug 6, 2014 | GlobeNewswire

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the second quarter ended June 30, 2014.

    Comment?

  9. Gevo CEO Sees Minnesota Biofuels Plant Breaking Even This YearRead the original story

    Aug 1, 2014 | The Washington Post

    ... from plant waste has proven technologically and economically challenging. Alan Shaw, former chief executive of Codexis Inc., the first advanced biofuel company to be publicly traded in the U.S., last year called the industry a "nightmare." He gave ...

    Comment?

  10. Codexis, Inc. To Announce Second Quarter 2014 Financial Results On August 6, 2014Read the original story

    Aug 1, 2014 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will host a live conference call and audio webcast on Wednesday, August 6, 2014 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results.

    Comment?

  11. Gordon Sangster To Join Codexis, Inc. As Senior Vice President & Chief Financial OfficerRead the original story

    Jul 29, 2014 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that Gordon Sangster has agreed to join Codexis as Senior Vice President & Chief Financial Officer.

    Comment?

  12. Codexis' CEO Presents at Corporate ConferenceRead the original story

    Jul 15, 2014 | Seeking Alpha

    Good day ladies and gentlemen and welcome to Codexis' Special Investor Conference call.

    Comment?

  13. GlaxoSmithKline will pay up to $25 million for protein-engineering techRead the original story w/Photo

    Jul 14, 2014 | SFGate

    British pharmaceutical giant GlaxoSmithKline will pay up to $25 million, plus potential additional payments, to use the protein-engineering technology of Redwood City company Codexis, the companies said Monday.

    Comment?

  14. Codexis (CDXS) Multimillion-Dollar Protein Engineering Platform...Read the original story

    Jul 15, 2014 | I-Newswire.com

    ... and the production of toxic waste, and reduce the energy intensity of the process. Pharmaceutical manufacturers use Codexis' (CDXS) biotechnology platform to increase purity and yields and produce less toxic waste. Codexis (CDXS) reported the ...

    Comment?

  15. Morning Market MoversRead the original story

    Jul 15, 2014 | Benzinga

    Codexis rose 82.27% to $2.57 after the company announced the signing of a platform technology license agreement with GlaxoSmithKline .

    Comment?

  16. GSK invests up to $25M in new drug manufacturing technology - in Pa., not N.C.Read the original story w/Photo

    Jul 15, 2014 | Local Tech Wire

    ... costs and improving sustainability. In a deal announced Monday, GSK (NYSE: GSK ) and Redwood, Calif.-based Codexis (Nasdaq: CDXS ) announced the licensing deal for "CodeEvolver," a protein engineering technology. Another $38.5 million could also be ...

    Comment?

  17. GlaxoSmithKline Invests Up To $25 Million In Codexis, Inc.'s New Drug Manufacturing TechnologyRead the original story

    Jul 15, 2014 | BioSpace

    Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the signing of a platform technology license agreement with GlaxoSmithKline .

    Comment?

  18. Targacept's Key Drug Failed Phase 2b Trial; ARIAD Announces...Read the original story

    Jul 14, 2014 | Hispanic Business

    In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment.

    Comment?

  19. Codexis +84% AH on Glaxo licensing pactRead the original story

    Jul 14, 2014 | Seeking Alpha

    Codexis +84.4% AH on news it granted a license to GlaxoSmithKline to use its CodeEvolver platform technology to develop enzymes for use in pharmaceutical and health care products.

    Comment?

  20. Synthetic Biology Market Is Expected to Reach $38.7 Billion,...Read the original story

    Jun 5, 2014 | SBWire

    ... of the strategic moves by key companies. Companies profiled in the report include BASF, GEN9 Inc., Algenol Biofuels, Codexis Inc., Gensript Corporation, Dupont, Butamax Advanced Biofuels, BioAmber, BioSearch Technologies, Inc., Origene Technologies, ...

    Comment?